Xuanzhu Biopharmaceutical Co., Ltd. (the "Company") reported that its total authorised/registered share capital remained at RMB 517.95 million (par value RMB 1 per share) as of 28 February 2026. The issuance consists of 160.70 million H shares listed on the Hong Kong Stock Exchange and 357.25 million unlisted shares.
No change was recorded in the share structure for the month, and the Company confirmed its compliance with the public float threshold of 24.96%. No new share issuances, share repurchases, convertibles, or warrants were disclosed during this period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments